Cerebras Looks Too Expensive

Conviction: 68% · Horizon: 6M · 2026-08-20
Cerebras prices in flawless inference share gains at a rich sales multiple

Cerebras still trades at a stretched multiple of near-term revenue after a hyped IPO, while usage, remaining-performance-obligation conversion, and margin expansion remain unproven. Nvidia already offers cheaper, scaled exposure to AI compute, so the risk/reward in Cerebras is poor until the market cap compresses toward a more reasonable sales multiple.

Instrument Side Target Reason
CBRS Short A wafer-scale inference story can be real and still be a bad stock at roughly 50x-plus near-term sales, with negative operating margins and execution still unproven versus Nvidia. That multiple leaves little room for slower RPO conversion, weaker usage, or delayed margin expansion.

Themes

The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.